A 40-year-old woman suffering from VHL disease presented for evaluation of the findings of a positron emission tomography/magnet resonance imaging (MRI) which was performed to monitor an osteodestructive sacral haemangioblastoma. The results of the imaging showed numerous cystic tumours and a single solid tumour of the pancreas as well as a retroumbilical mass. Consultant radiological opinion considered the solid tumour to be a pancreatic neuroendocrine tumour (pNET) with a retroumbilical metastasis.
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Pancreatic involvement is diagnosed in 50-80% of patients with VHL disease [4] . In about 8% of cases pancreatic manifestations occur solely and are either cystic or solid tumours. Solid masses are mostly neuroendocrine tumours, while cystic lesions are rather simple cysts or serous cystadenomas [5] . Therefore, most pancreatic lesions are benign, but malignant or premalignant tumours such as intrapancreatic mucinous neoplasms or metastases of renal cell carcinoma need to be excluded [6] . 5-17% of VHL disease patients suffer from pNET [7] . These neoplasms are malignant in 17% [8] . Most neuroendocrine tumours do not influence physiological processes by secretion of hormones, but there is a risk of dissemination to distant organs or of local advancement. At the time of diagnosis, up to 25% of the neoplasms have already metastasized [9] .
Surgical treatment is recommended for tumours >2 cm. If the tumour is <2 cm, resection should only be performed in case of at least G2 grading or if symptomatic, otherwise surveillance by annual MRI scans is advised. Whenever possible, oncological resection is to be aimed for [10] . Advanced stages of a pNET can be treated by chemotherapy, targeted drugs, or peptide receptor radionuclide therapy. For poorly differentiated tumours, G3 platinbased cytostatic agents are used [11] .
Conclusion
pNETs are found in <17% of patients with VHL disease. Generally, guidelines recommend a surgical treatment if the tumour is >2 cm. In our case, however, a hemipancreaticoduodenectomy needed to be performed despite a pNET tumour size <2 cm, because metastatic spread could not be excluded in histopathological testing. Additional pancreatic lesions were lined with epithelium and considered as acinar cell cystadenomas.
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